Stiefel Laboratories Expands Through Strategic Acquisitions

Stiefel Laboratories has made significant strides in expanding its reach through strategic acquisitions. This growth strategy has allowed the company to tap into new markets and increase its product offerings.

One notable acquisition was the purchase of a dermatological research facility, which enabled Stiefel to develop new treatments for skin conditions.

By expanding its portfolio through acquisitions, Stiefel Laboratories has been able to establish itself as a leading player in the dermatological industry.

Stiefel Laboratories has been expanding its reach through strategic acquisitions and mergers. The company's commitment to advancing dermatology is evident in its bold moves.

Stiefel Laboratories acquired Connetics Corporation, merging their innovative skin care products with Connetics' advanced therapies and patented drug-delivery technologies. This created one of the largest dermatology product pipelines in the world.

The acquisition of Connetics marked a significant milestone in Stiefel Laboratories' history, with Charles W. Stiefel, Chairman and CEO, stating that the company is well on its way to reaching its goal of $1 billion in product sales.

Stiefel Laboratories also acquired Barrier Therapeutics for approximately $148 million, gaining three marketed drugs and five candidates in various stages of clinical development. This strategic move further expanded Stiefel Laboratories' oral and topical product portfolio in development.

Related reading: Divi's Laboratories

Stiefel Laboratories acquired Connetics Corporation, a publicly held specialty pharmaceutical company focused on the dermatology market.

The acquisition united innovative skin care products and commercial capabilities of Stiefel Laboratories with advanced therapies and patented drug-delivery technologies of Connetics.

This deal created one of the largest dermatology product pipelines in the world, merging technology and development expertise.

Charles W. Stiefel, Chairman and Chief Executive Officer of Stiefel Laboratories, described the acquisition as a significant milestone in the company's history.

The acquisition enhanced Stiefel Laboratories' product portfolio, positioning the company well to reach its goal of achieving $1 billion in product sales.

Connetics provided Stiefel Laboratories with delivery technologies and expertise that can be applied to many of its existing products.

This acquisition ultimately benefits dermatology patients around the world by providing them with access to innovative products and technologies.

Stiefel Laboratories is acquiring Barrier Therapeutics for approximately $148 million, a significant deal in the dermatology space.

The acquisition price of $4.15 per share represents a 135% premium over Barrier Therapeutics' previous day closing price.

Barrier Therapeutics' stock skyrocketed from $1.76 at close on Friday to open today at $3.99, a notable increase.

The transaction is expected to close by the end of the third quarter, marking a significant milestone for both companies.

Stiefel Laboratories will gain three marketed drugs as a result of the acquisition, expanding its product portfolio.

Barrier Therapeutics will also bring five candidates in various stages of clinical development to the table, further bolstering Stiefel's pipeline.

For more insights, see: Gsk Ticker Symbol

Stiefel Laboratories operates in a competitive industry with several key players, including Combe Inc., Medicis Pharmaceutical Corporation, Skin-Medica, Inc., NuSkin Enterprises Inc., and Allergan, Inc.

One of these competitors, Combe Inc., is mentioned in a 1993 article from the Atlanta Journal and Constitution, which highlights the growth of the company in the same year Stiefel Laboratories was expanding its operations.

Stiefel Laboratories has a long history of focus on skin and its health, dating back to 1847, as mentioned in a 1997 Business Wire article celebrating the company's 150 years in the industry.

Recommended read: Ishares Inc Core Msci Emkt

Stiefel's global expansion was a key factor in its success, with the company relocating its headquarters to Coral Gables, Florida, in 1977 to be closer to the growing Latin American market.

By the mid-1990s, Stiefel had 1,100 employees around the world and annual revenues of $250 million. This rapid expansion continued, with the company adding hundreds more employees by the end of the decade.

Stiefel established a massive new plant in Brazil around 1999, which was billed as the largest pharmaceutical plant in the southern hemisphere at nearly 250,000 square feet. This plant had over 400 employees and sales of about $70 million in Brazil.

In late 2000, Stiefel entered India through a joint venture, establishing a manufacturing and distribution unit. This marked the company's first foreign entry via a joint venture, although it would later buy out its minority partner, Elder Pharmaceuticals Limited.

By 2001, Stiefel was active in more than 100 countries through its three-dozen subsidiaries, with a workforce of 1,500 employees and annual revenues of $250 million.

Explore further: IShares S&P Global 100

Combe Inc. and Medicis Pharmaceutical Corporation are notable competitors in the industry. They're major players that have been mentioned alongside Stiefel Laboratories in various reports.

Combe Inc. has been involved in the market for a while, with a notable mention in a 1993 article about a new plant in Suwanee. Their presence is a significant factor to consider when looking at the industry landscape.

Medicis Pharmaceutical Corporation is another key competitor, with a notable mention in a 1997 article celebrating Stiefel Laboratories' 150-year focus on skin and its health. This highlights the long-standing presence of these companies in the industry.

Skin-Medica, Inc. is also a competitor worth noting, although there isn't much information available about them from the provided sources. However, they're listed as a competitor alongside the other companies mentioned.

NuSkin Enterprises Inc. is another company that's been mentioned as a competitor, but there's limited information available about their specific involvement in the industry.

Here's an interesting read: ACT Biotech Inc

Stiefel works tirelessly to advance dermatology through its research and development efforts, allowing the company to deliver new and innovative skin care solutions.

The company's strong relationships with the dermatology community provide keen insights and appreciation for the needs of the global skin care community. This has led to the development of products that cater to those needs.

Stiefel's passion for advancing dermatology is unwavering, and it shows in the company's commitment to delivering high-quality, dermatologist-developed formulations that work.

The company's U.S. Consumer Health Care Division achieved 20% growth in 2008, and it will continue to fuel expansion through strategic relationships with key retailers and new product introductions.

Stiefel's Impruv Dry Skin product line features Impruv Natural Repair Lotion and Cream, which replenishes the lipids that skin produces naturally with six botanicals.

On a similar theme: Is It Mandatory to Have Health Insurance in New York

Stiefel Laboratories was founded in the early days of the company's expansion, with the 1970s marking a significant period of growth. The company expanded into South and Central America, the Caribbean, and France during this time.

Between 1970 and 1979, Stiefel averaged a remarkable 50% growth every year, with sales reaching $10.4 million by the end of the decade. This rapid expansion was a testament to the company's innovative approach and dedication to its customers.

In 1977, the company relocated its headquarters to Coral Gables, Florida, a strategic move that would help it navigate the changing landscape of the industry. This move marked a significant milestone in the company's history.

The 1980s saw Stiefel establish its first research and development facility outside of the US in Slough, a town near the company's United Kingdom headquarters. This facility was later moved to Maidenhead.

Stiefel continued to expand its operations, establishing subsidiaries in over 30 countries and relationships with distributors in 70 others by the end of the decade. The company's factories were operating in Ireland, Brazil, Singapore, and Mexico, supplying markets around the world.

By the 1990s, Stiefel Laboratories had become a global leader in the dermatology market, with sales reaching $180 million by the end of the decade. The company's focus on innovation and customer satisfaction had paid off.

In 1991, Stiefel founded Glades Pharmaceuticals to market generic dermatology products, a move that would further solidify the company's position in the market. This marked the beginning of a new era for Stiefel.

The 2000s saw Stiefel introduce a new brand of skin care products, Physiogel, which would go on to become a best-seller. This marked a significant shift in the company's focus towards more consumer-friendly products.

In 2006, Stiefel made its first major corporate acquisition, purchasing California-based Connetics Corporation. This move marked a significant milestone in the company's history, solidifying its position as a leader in the industry.

Stiefel continued to innovate, launching MaxClarity and receiving FDA approval for two Rx products in the United States, Sorilux Foam and Veltin Gel, in 2010.